Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011
- 18 April 2022
- journal article
- editorial
- Published by Elsevier in European Urology Focus
- Vol. 8 (3) , 646-647
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomyAnnals of Oncology, 2021
- ctDNA guiding adjuvant immunotherapy in urothelial carcinomaNature, 2021
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2021